MiniMed Flex insulin pump receives FDA clearance months early; $157M charge expected in Q4 FY2026

MiniMed Group, Inc.

FDA cleared MiniMed Flex insulin pump several months earlier than expected, enabling earlier commercialization.
R&D was funded by Blackstone; Blackstone to earn greater of mid-to-high single digit royalty or min $157M payment.
MiniMed will record a one-time charge of $157 million in Q4 FY2026 for future payments due to Blackstone.
MiniMed Flex is a next-generation, smartphone-controlled insulin pump with a discreet design.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.